Sciatica refers to pain that radiates along the path of the sciatic nerve, which branches from your lower back through your hips and buttocks and down each leg. Companies addressing sciatica may be involved in developing treatments, medications, medical devices, or therapies aimed at managing and alleviating sciatic nerve-related pain.
NeuroBio Pharmaceuticals announced a breakthrough gene therapy for sciatica pain management called NeuroGeneSci. This novel approach targets specific genes associated with nerve inflammation and aims to provide long-term relief for chronic sciatica patients. (Mar 23, 2023)
SciaticaCare received FDA approval for their NeuroWave, a non-invasive nerve stimulation device. This device delivers targeted electrical stimulation to the affected nerve roots, reducing inflammation and relieving sciatic pain. It offers a safe and effective alternative to invasive treatments like surgery. (Jun 23, 2023)
Researchers at the University of California, San Diego are studying the potential of using artificial intelligence (AI) to predict and personalize treatment for sciatica. This could lead to more targeted and effective interventions for individual patients. (Dec 22, 2023)
Sorrento Therapeutics' subsidiary Scilex Holding Company received Fast Track designation from the FDA for SP-102 (SEMDEXA), an injectable dexamethasone sodium phosphate viscous gel for lumbosacral radicular pain or sciatica. This fast-acting treatment demonstrated pain relief that continued through 12 weeks in clinical trials.
AbbVie and Regeneron are collaborating on a Phase 3 trial to evaluate the efficacy and safety of their IL-6 receptor inhibitor, upadacitinmab, for the treatment of moderate-to-severe chronic sciatica. This collaboration leverages expertise in both companies to tackle this challenging condition.
List of Sciatica companies in the market
Sciatica Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)